BioVersys AG (XSWX:BIOV) Total Debt per Share: CHF3.72 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.50
View Full Analysis

What is BioVersys AG Total Debt per Share?

BioVersys AG XSWX:BIOV +1.92% 4 Total Debt per Share is CHF3.72 as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

CHF3.72 (As of Dec. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. BioVersys AG's Total Debt Per Share for the quarter that ended in Dec. 2025 was CHF3.72.

BioVersys AG Total Debt per Share Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Debt per Share Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Total Debt per Share
2.87 3.72

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Total Debt per Share 0.00 2.87 3.13 3.72
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Total Debt per Share Calculation

BioVersys AG's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(21.44+0.29)/5.85
=3.72

BioVersys AG's Total Debt Per Share for the quarter that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(21.44+0.29)/5.85
=3.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of CHF3.72 mean?
BioVersys AG (XSWX:BIOV) has a Total Debt per Share of CHF3.72 as of Dec. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Total Debt per Share too high?
BioVersys AG's current Total Debt per Share is CHF3.72. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Total Debt per Share compare to VRTX and REGN?
BioVersys AG's Total Debt per Share of CHF3.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on BioVersys AG and its competitors. BioVersys AG's current Total Debt per Share is CHF3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Total Debt per Share of CHF3.72. The current Total Debt per Share is CHF3.72. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Total Debt per Share is CHF3.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.50
Price